Outcome of immune checkpoint inhibitors in patients with extensive-stage small-cell lung cancer and brain metastases.

ABSTRACT:

Objectives

Brain metastases (BMs) are common in extensive-stage small-cell lung cancer (SCLC) and are underrepresented in pivotal clinical trials that demonstrate the efficacy of immune checkpoint inhibitors (ICIs). We conducted a retrospective analysis to assess the role of ICIs in BM lesions in less selected patients.

Materials and methods

Patients with histologically confirmed extensive-stage SCLC who were treated with ICIs were included in this study. Objective response rates (ORRs) were compared between the with-BM and without-BM groups. Kaplan-Meier analysis and the log-rank test were used to evaluate and compare progression-free survival (PFS). The intracranial progression rate was estimated using the Fine-Gray competing risks model.

Results

A total of 133 pati

SUBMITTER: Wang C 

PROVIDER: S-EPMC10196483 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature